IM
IMNN
Imunon, Inc.
$2.02
-0.49%
$8.5M
No data for this timeframe.
Vol
Market Cap$8.5M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders9 funds
Inst. Value$212.2K
Inst. Activity0 buys / 1 sells
SEC Reports4
Press Releases1
Recent Activity
Jun 5, 2026
Insider
Lindborg Stacy was granted 1,593 shares
President and CEO @ $2.06 ($3.3K)
Jun 5, 2026
Insider
Tardugno Michael H was granted 4,089 shares
Executive Chairman of Board @ $2.06 ($8.4K)
Jun 4, 2026
SEC
Imunon entered into a $10M financing with Streeterville Capital, consisting of $2.5M from 250 shares of non-convertible
8-K — Impact 6/10
Jun 4, 2026
other
IMUNON Announces Up to $10 Million Cash Financing
<p align="center">Includes up-front issuance of preferred stock for $2.5 million and secured <br>pro
May 22, 2026
Insider
Fritz Frederick J. was granted 10,330 shares
Director @ $2.20 ($22.7K)
May 12, 2026
SEC
Imunon reported Q1 2026 GAAP EPS of -$0.84, beating consensus of -$0.99 by 15%, but operating cash burn widened to -$4.0
8-K — Impact 6/10
May 4, 2026
SEC
Imunon entered into change-in-control severance agreements with its CEO, CMO, and General Counsel, providing 2.5x (CEO)
8-K — Impact 2/10
Inst.
GROUP ONE TRADING LLC — TRIM
6 shares ($18.00)
Price Targets
$17.00
+741.6% upside
Strong Buy
Current $2.02
Low $10.00
Median $13.00
High $25.00
5 analysts
$10.00
$25.00
Analyst Ratings
2Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 17, 2026 | Maxim Group | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.57 ▲ +44.3% | $-0.68 — $-0.46 | 70% YoY | 2 |
| Next Q | $-0.60 ▲ +16.0% | $-0.74 — $-0.47 | 48% YoY | 2 |
| Current FY | $-2.52 ▲ +24.2% | $-3.00 — $-2.05 | 63% YoY | 2 |
| Next FY | $-2.18 ▼ -14.1% | $-3.11 — $-1.63 | 14% YoY | 4 |
Latest Reports
BEARISH
8-K
6/10
Imunon entered into a $10M financing with Streeterville Capital, consisting of $2.5M from 250 shares of non-convertible
Jun 4, 2026
BULLISH
8-K
6/10
Imunon reported Q1 2026 GAAP EPS of -$0.84, beating consensus of -$0.99 by 15%, but operating cash burn widened to -$4.0
May 12, 2026
NEUTRAL
Press
3/10
Imunon, Inc. announced it will host a conference call on March 31, 2026, to discuss its 2025 financial results and provi
Mar 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | NEAR_EXIT |
| VANGUARD CAPITAL MANAGEMENT LLC | $141.3K | — |
| VANGUARD FIDUCIARY TRUST CO | $39.0K | — |
| BlackRock, Inc. | $13.1K | — |
| WELLS FARGO & COMPANY/MN | $9.8K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Lindborg Stacy | A | $3.3K |
| Jun 5, 2026 | Tardugno Michael | A | $8.4K |
| May 22, 2026 | Fritz Frederick | A | $22.7K |
| May 22, 2026 | Lindborg Stacy | A | $3.3K |
| May 22, 2026 | Pellizzari Christine | A | $12.2K |
9 institutional holders with $212.2K total value (84,229 shares) as of 2026-Q1. Top holders: ROYAL, VANGUARD, VANGUARD. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 1 | $0.00 | 0.0% | NEAR_EXIT -100.0% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 48,056 | $141.3K | 66.6% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 13,269 | $39.0K | 18.4% | — |
| 4 | BlackRock, Inc. | 4,464 | $13.1K | 6.2% | — |
| 5 | WELLS FARGO & COMPANY/MN | 3,342 | $9.8K | 4.6% | — |
| 6 | MORGAN STANLEY | 3,035 | $8.9K | 4.2% | TRIM -34.3% |
| 7 | HRT FINANCIAL LP | 12,055 | $35.00 | 0.0% | — |
| 8 | GROUP ONE TRADING LLC | 6 | $18.00 | 0.0% | TRIM -33.3% |
| 9 | FMR LLC | 1 | $3.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| GROUP ONE TRADING LLC | TRIM | 9 | 6 | -33.3% | $18.00 | 2026-Q1 |
| VANGUARD GROUP INC | ADD | 23,301 | 37,052 | +59.0% | $141.2K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 4,509 | 2,964 | -34.3% | $11.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 42 | 27 | -35.7% | $103.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 10,442 | 638,000 | +6009.9% | $510.4K | 2025-Q2 |
| VANGUARD GROUP INC | DOUBLED | 48,806 | 190,487 | +290.3% | $152.4K | 2025-Q2 |
| UBS Group AG | DOUBLED | 22 | 15,339 | +69622.7% | $12.3K | 2025-Q2 |
| ROYAL BANK OF CANADA | NEAR_EXIT | 40,097 | 2 | -100.0% | — | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 33,561 | 10,442 | -68.9% | $11.0K | 2025-Q1 |
| ROYAL BANK OF CANADA | DOUBLED | 2 | 40,097 | +2004750.0% | $38.0K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 63,611 | 33,561 | -47.2% | $31.9K | 2024-Q4 |
| MORGAN STANLEY | ADD | 1,631 | 2,131 | +30.7% | $2.3K | 2024-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 77 | 118 | +53.2% | $125.00 | 2024-Q3 |
6 unique insiders with 8 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Lindborg Stacy | President and CEO | AWARD | 1,593 | $2.06 | $3.3K |
| Jun 5, 2026 | Tardugno Michael H | Executive Chairman of Board | AWARD | 4,089 | $2.06 | $8.4K |
| May 22, 2026 | Fritz Frederick J. | Director | AWARD | 10,330 | $2.20 | $22.7K |
| May 22, 2026 | Lindborg Stacy | President and CEO | AWARD | 1,491 | $2.20 | $3.3K |
| May 22, 2026 | Pellizzari Christine A | Director | AWARD | 5,557 | $2.20 | $12.2K |
| May 22, 2026 | Dentzer James E | Director | AWARD | 11,148 | $2.20 | $24.5K |
| May 22, 2026 | Braun Donald P | Director | AWARD | 5,011 | $2.20 | $11.0K |
| May 22, 2026 | Tardugno Michael H | Executive Chairman of Board | AWARD | 3,484 | $2.20 | $7.7K |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 1 neutral. Avg impact: 5.0/10.
BEARISH
8-K
6/10
Imunon entered into a $10M financing with Streeterville Capital, consisting of $2.5M from 250 shares
Jun 4, 2026
BULLISH
8-K
6/10
Imunon reported Q1 2026 GAAP EPS of -$0.84, beating consensus of -$0.99 by 15%, but operating cash b
May 12, 2026
NEUTRAL
8-K
2/10
Imunon entered into change-in-control severance agreements with its CEO, CMO, and General Counsel, p
May 4, 2026
MIXED
8-K
6/10
Imunon reported a 2025 net loss of $14.5 million (EPS $-6.83), missing consensus by 55.9%, but highl
Apr 21, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 2 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$17.00 mean target
+741.6% upside
Strong Buy (1.25)
$10.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $2.02 |
| Target Low | $10.00 |
| Target Mean | $17.00 |
| Target Median | $13.00 |
| Target High | $25.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.57 | $-0.68 | $-0.46 | 69.5% | +44.3% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.60 | $-0.74 | $-0.47 | 47.8% | +16.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-2.52 | $-3.00 | $-2.05 | 63.0% | +24.2% | 1↑ 1↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-2.18 | $-3.11 | $-1.63 | 13.6% | -14.1% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.570 | |
| 7d ago | $-0.460 | -0.110 |
| 30d ago | $-1.023 | +0.453 |
| 60d ago | $-0.860 | +0.290 |
| 90d ago | $-0.737 | +0.167 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 17, 2026 | Maxim Group | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Mar 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Feb 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Jan 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
other
IMUNON Announces Up to $10 Million Cash Financing
<p align="center">Includes up-front issuance of preferred stock for $2.5 million and secured <br>promissory notes for $7.72 million</p>
May 12, 2026
earnings_calendar
IMNN Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings_calendar
IMNN Q1 2026 Earnings Scheduled — 2026-05-11
Mar 31, 2026
earnings_calendar
IMNN Q4 2025 Earnings After Market Close — 2026-03-31
Mar 26, 2026
earnings_calendar
IMNN Q4 2025 Earnings After Market Close — 2026-03-26
Mar 25, 2026
other
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
<p align="center">The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 1
Mar 24, 2026
earnings
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
<p align="justify"><b>LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- </b><a href="https://www.globenewswire.com/Tracker?data=eB-LXLuOTX6-zC
Feb 25, 2026
earnings_calendar
IMNN Q4 2025 Earnings After Market Close — 2026-02-25